These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 16787142

  • 1. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [Abstract] [Full Text] [Related]

  • 2. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
    Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M.
    Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
    [Abstract] [Full Text] [Related]

  • 3. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
    Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T.
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
    [Abstract] [Full Text] [Related]

  • 4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 5. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
    Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D.
    Expert Opin Investig Drugs; 2002 Feb 01; 11(2):283-93. PubMed ID: 11829717
    [Abstract] [Full Text] [Related]

  • 6. Hormone therapy of prostatic bone metastases.
    Huben RP.
    Adv Exp Med Biol; 1992 Feb 01; 324():305-16. PubMed ID: 1492625
    [Abstract] [Full Text] [Related]

  • 7. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.
    BJU Int; 2007 Jul 01; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract] [Full Text] [Related]

  • 8. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ, Radiation Therapy Oncology Group P-0014.
    Urology; 2003 Dec 29; 62 Suppl 1():95-101. PubMed ID: 14747047
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F, Dupont A, Bélanger A, Lacourcière Y, Monfette JE, Monfette G.
    Ann Urol (Paris); 1986 Dec 29; 20(2):98-106. PubMed ID: 2940959
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.
    Urology; 2003 Jul 29; 62(1):99-104. PubMed ID: 12837431
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J, Monfette G.
    J Steroid Biochem; 1987 Jul 29; 27(1-3):525-32. PubMed ID: 2961937
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.